Receipt of novel hormonal therapy for advanced prostate cancer varies with race
For Medicare beneficiaries with advanced prostate cancer (PCa), receipt of novel hormonal therapy (NHT) agents varies with race, according to a study published online Dec. 1 in JAMA Network Open. Ting Martin Ma, M.D., Ph.D., from the University of Washington in Seattle, and colleagues examined racial and ethnic disparities in use of NHT in a …
Receipt of novel hormonal therapy for advanced prostate cancer varies with race Read More »